adult tcell leukemialymphoma atl atll rare cancer immune systems caused human cell leukemialymphotropic virus type atl cells contain integrated provirus supporting causal role virus cause small amount individuals progress develop atl long latency period infection atl development atl categorized subtypes acute smoldering lymphomatype chronic acute lymphomatype known particularity aggressive poorer globally retrovirus estimated infect million people incidence atl approximately per endemic regions regions japan high per however cases increased nonendemic regions highest incidence southernnorthern islands japan caribbean central south america intertropical africa romania northern iran atl normally occurs around age years median age diagnosis depend prevalence infection geographic current treatment regiments atl based clinical subtype response initial therapy therapy modalities treatment may available countries therefore strategies differ across world patients referred clinical trials available beyond clinical trials treatments centered multiagent chemotherapy zidovudine plus interferon aztifn allogenic hematopoietic stem cell transplantation atl usually highly aggressive nonhodgkins lymphoma characteristic histologic appearance except diffuse pattern mature tcell circulating lymphocytes irregular nuclear contour leukemic cells frequently seen several lines evidence suggest causes atl evidence includes frequent isolation patients disease detection proviral genome atl leukemic cells atl frequently accompanied visceral involvement hypercalcemia skin lesions lytic bone lesions bone invasion osteolysis features bone metastases commonly occur setting advanced solid tumors breast prostate lung cancers less common hematologic malignancies however patients atl multiple myeloma predisposed development tumorinduced osteolysis hypercalcemia one striking features atl multiple myeloma induced bone disease bone lesions predominantly osteolytic little associated osteoblastic activity patients atl elevated serum levels tgfβ pthrp macrophage inflammatory protein receptor activator nuclear factorκb ligand rankl associated hypercalcemia immunodeficient mice received implants leukemic cells patients atl lymphocytes developed hypercalcemia elevated serum levels patients die within one year infection like infection retroviruses probably occurs life inferred antibody detected transmission believed occur mother child sexual contact exposure contaminated blood either blood transfusion sharing contaminated diagnosis made based combination clinical features characteristic morphologic immunophenotypic changes malignant cells clinical features prognosis diverse disease subtypeclassified four categories according shimoyama classification acute lymphoma chronic normally identification least percent tumor cells peripheral blood confirmation human tlymphotropic virus sufficient diagnosis acute chronic smoldering types lymphoma type histopathologic examination biopsy lymph nodes may treatment options tried include zidovudine chop pralatrexate also recently reported traditional glucocorticoidbased chemotherapy toward atl largely mediated thioredoxin binding suggesting potential use inducer novel therapeutic mogamulizumab approved relapsedrefractor treatment atl medical conference december researchers reported anywhere atl patients disease expressing although fda approved treatment brentuximab vedotin cd cases may beneficial supported current nccn infection united states appears rare although little serologic data exist prevalence infection thought highest among blacks living southeast prevalence rate found among black intravenous drug abusers new jersey rate found similar group new orleans possible prevalence infection increasing risk group studies antibody indicate virus endemic southern japan caribbean south america atl relatively uncommon among infected overall incidence atl estimated per adult carriers per year cases reported occurred mostly among persons caribbean blacks southeast national institutes health unpublished data appears long latent period infection start novel approaches treatment ptcl relapsed refractory setting investigation pralatrexate one compound currently investigations treatment aggressive sézary disease httpsenwikipediaorgwikiadulttcellleukemialymphoma